IL6 and urinary bladder carcinoma: Research has demonstrated that inflammatory cytokines (e.g., IL-6, TNF-α) can inhibit erythrocyte maturation, leading to increased RDW (19), while simultaneously activating oncogenic pathways such as STAT3, promoting tumorigenesis, immune evasion, and driving bladder cancer progression (20).